John Mondick

Cystic fibrosis

Irinotecan and its active metabolite, SN‐38: review of bioanalytical methods and recent update from clinical pharmacology perspectives

Consensus Guidelines for the Management of Postoperative Nausea and Vomiting

Analysis of anticancer drugs: A review

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Clinical pharmacokinetics of tyrosine kinase inhibitors

Cystic fibrosis and the role of gastrointestinal outcome measures in the new era of therapeutic CFTR modulation

Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS®) Society and the European Society of Thoracic Surgeons (ESTS)

Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis

Obiltoxaximab: Adding to the Treatment Arsenal for Bacillus anthracis Infection

Guidelines for Perioperative Care in Elective Rectal/Pelvic Surgery: Enhanced Recovery After Surgery (ERAS^®) Society Recommendations

Antimicrobial Resistance in ESKAPE Pathogens

Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children

Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults

Diagnosing malabsorption with systemic lipid profiling: pharmacokinetics of pentadecanoic acid and triheptadecanoic acid following oral administration in healthy subjects and subjects with cystic fibrosis

Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1−48 months

Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children’s oncology group

Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity

Delayed Small Bowel Transit in Children With Cystic Fibrosis and Pancreatic Insufficiency